Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 14/20 | 0.83 |
| ▸ | PTGES | O14684 | 1/20 | 0.69 |
| ▸ | PPARG | P37231 | 3/20 | 0.59 |
| ▸ | PPARA | Q07869 | 2/20 | 0.59 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.59 |
| ▸ | AKT1 | P31749 | 2/20 | 0.56 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.56 |
| ▸ | PHLPP1 | O60346 | 1/20 | 0.56 |
| ▸ | ILK | Q13418 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29465604 | 1.00 | ALOX5 (0.83) | ALOX5PTGESPPARGPPARANR1I2 | |
| Gamma-Tocotrienol SCHEMBL16430897 | 1.00 | ALOX5 (0.83) | ALOX5PTGESPPARGPPARANR1I2 | |
| Gamma-Tocotrienol SCHEMBL3272929 | 1.00 | ALOX5 (0.83) | ALOX5PTGESPPARGPPARANR1I2 | |
| Gamma-Tocotrienol SCHEMBL3270920 | 1.00 | ALOX5 (0.83) | ALOX5PTGESPPARGPPARANR1I2 | |
| Gamma-Tocotrienol SCHEMBL29354672 | 1.00 | ALOX5 (0.83) | ALOX5PTGESPPARGPPARANR1I2 | |
| SCHEMBL17523133 | 0.93 | ALOX5 (0.71) | ALOX5PTGESPPARGPPARANR1I2 | |
| SCHEMBL12368109 | 0.93 | ALOX5 (0.71) | ALOX5PTGESPPARGPPARANR1I2 | |
| SCHEMBL18583914 | 0.93 | ALOX5 (0.88) | ALOX5PTGESPPARGPPARANR1I2 | |
| SCHEMBL18583915 | 0.91 | ALOX5 (1.00) | ALOX5PTGESPPARGPPARANR1I2 | |
| SCHEMBL16589599 | 0.90 | ALOX5 (0.68) | ALOX5PTGESPPARGPPARANR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11202814-B2 | Compositions for atopic skin | INFINITEC ACTIVOS, S.L. (ES) | 2021-12-21 | — | — | US | disclosed |
| US-20190240271-A1 | COMPOSITIONS FOR ATOPIC SKIN | INFINITEC ACTIVOS, S.L. (ES) | 2019-08-08 | — | — | US | disclosed |
| EP-3520774-A1 | COMPOSITIONS FOR ATOPIC SKIN | Infinitec Activos S.L. (ES) | 2019-08-07 | — | — | EP | disclosed |
| EP-3348253-B1 | LOW-ALCOHOL ORAL CARE COMPOSITIONS COMPRISING ETHYL LAUROYL ARGINATE | LACER SA (ES) | 2019-07-17 | — | — | EP | disclosed |
| EP-3348253-A1 | LOW-ALCOHOL ORAL CARE COMPOSITIONS COMPRISING ETHYL LAUROYL ARGINATE | Lacer, S.A. (ES) | 2018-07-18 | — | — | EP | disclosed |
| US-20160324823-A1 | TREATMENT OF MITOCHONDRIAL DISEASES | BIOELECTRON TECHNOLOGY CORPORATION | 2016-11-10 | — | — | US | disclosed |
| US-20130267538-A1 | TREATMENT OF MITOCHONDRIAL DISEASES | GALILEO PHARMACEUTICALS INC. | 2013-10-10 | — | — | US | disclosed |
| EP-1270004-B1 | USE OF GAMMA-TOCOTRIENOL AS DIURETIC | EISAI R&D MAN CO LTD (JP) | 2010-06-09 | — | — | EP | disclosed |
| EP-1044687-B1 | POWDERS CONTAINING TOCOTRIENOLS AND TABLETS PREPARED BY COMPRESSION MOLDING THE SAME | FUJI CHEM IND CO LTD (JP) | 2008-09-03 | — | — | EP | disclosed |
| US-7074825-B2 | Composition and method for treating cancer | MO HUANBIAO | 2006-07-11 | — | — | US | disclosed |
| WO-2005032544-A1 | TREATMENT OF MITOCHONDRIAL DISEASES | GALILEO PHARMACEUTICALS, INC. (US) | 2005-04-14 | — | — | WO | disclosed |
| US-20050065099-A1 | Alzheimer's disease; Parkinson's disease; brain disorders; antiepileptic agents; amyotrophic lateral sclerosis; vision defects | EDISON PHARMACEUTICALS, INC. | 2005-03-24 | — | — | US | disclosed |
| US-6864280-B2 | Hypotensive agents; cardiovascular disorders | EISAI CO., LTD. (JP) | 2005-03-08 | — | — | US | disclosed |
| US-20040176311-A1 | Composition and method for treating cancer | MO HUANBIAO (US) | 2004-09-09 | — | — | US | disclosed |
| US-20040110848-A1 | Method and kit for treating cancer | PEFFLEY DENNIS M | 2004-06-10 | — | — | US | disclosed |
| US-20030139467-A1 | Diuretics containing y-tocotrienol | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2003-07-24 | — | — | US | disclosed |
| EP-1270004-A1 | DIURETICS CONTAINING GAMMA-TOCOTRIENOL | Eisai Co., Ltd. (JP) | 2003-01-02 | — | — | EP | disclosed |
| US-6441029-B1 | D-.GAMMA.-TOCOTRIENOL, 2-DESMETHYLTOCOTRIENOL, D-.DELTA.-TOCOTRIENOL OR D-TOCOTRIENOL AND LOVASTATIN | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2002-08-27 | — | — | US | disclosed |
| EP-1044687-A1 | POWDERS CONTAINING TOCOTRIENOLS, PROCESS FOR PRODUCING THE SAME AND TABLETS PREPARED BY COMPRESSION MOLDING THE SAME | FUJI CHEMICAL INDUSTRY CO., LTD. (JP) | 2000-10-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065099-A1 | Alzheimer's disease; Parkinson's disease; brain disorders; antiepileptic agents; amyotrophic lateral sclerosis; vision defects | CLN6, LDHA, NLN | ALOX5 1992/4885PTGES 3403/4885PPARG 2137/4885 |
| US-20160324823-A1 | TREATMENT OF MITOCHONDRIAL DISEASES | NLN, FH, MFN2 | ALOX5 1604/4885PTGES 3079/4885PPARG 1252/4885 |
| US-11202814-B2 | Compositions for atopic skin | PNN, TSLP, CUTA | ALOX5 47/4885PTGES 131/4885PPARG 1357/4885 |
| US-20130267538-A1 | TREATMENT OF MITOCHONDRIAL DISEASES | NLN, FH, MFN2 | ALOX5 1604/4885PTGES 3079/4885PPARG 1252/4885 |
| US-20030139467-A1 | Diuretics containing y-tocotrienol | SLC26A4, SLC5A1, REN | ALOX5 170/4885PTGES 159/4885PPARG 611/4885 |
| US-20190240271-A1 | COMPOSITIONS FOR ATOPIC SKIN | PNN, TSLP, CUTA | ALOX5 47/4885PTGES 131/4885PPARG 1357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.